For the quarter ending 2025-12-31, CBT had -$28M decrease in cash & cash equivalents over the period. $57M in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net income (loss) | 82 | 54 | 322 |
| Depreciation and amortization | 41 | 40 | 114 |
| Deferred tax provision (benefit) | 2 | 23 | 9 |
| Equity in earnings of affiliated companies | 1 | 2 | 5 |
| Share-based compensation | 3 | 5 | 19 |
| Other non-cash (income) expense | -10 | -9 | -15 |
| Cash dividends received from equity affiliates | 1 | 0 | 13 |
| Accounts and notes receivable | -64 | -29 | -47 |
| Inventories | -2 | -28 | -19 |
| Prepaid expenses and other assets | 14 | -24 | 25 |
| Accounts payable and accrued liabilities | -61 | 12 | -79 |
| Income taxes payable | -7 | 2 | -10 |
| Other liabilities | 4 | -5 | 7 |
| Cash provided by (used in) operating activities | 126 | 219 | 446 |
| Additions to property, plant and equipment | 69 | 64 | 210 |
| Asset acquisition | - | 27 | - |
| Other | - | -5 | 2 |
| Cash paid for asset acquisition | - | - | 27 |
| Cash provided by (used in) investing activities | -69 | -59 | -239 |
| Proceeds from short-term borrowings | - | 5 | 14 |
| Repayments of short-term borrowings | - | 0 | 11 |
| Proceeds from issuance of (repayments of) commercial paper, net | - | -91 | 52 |
| Repayments of short-term borrowings (original maturities greater than 90 days) | 8 | - | - |
| Proceeds from long-term debt, net of issuance costs | - | 0 | 15 |
| Proceeds from (repayments of) short-term borrowings, net (original maturities 90 days or less) | 7 | - | - |
| Repayments of long-term debt | 2 | 2 | 5 |
| Purchases of common stock | 52 | 39 | 129 |
| Proceeds from sales of common stock | - | 6 | 2 |
| Cash dividends paid to noncontrolling interests | 13 | 0 | 57 |
| Cash dividends paid to common stockholders | 24 | 25 | 71 |
| Cash provided by (used in) financing activities | -92 | -146 | -190 |
| Effects of exchange rate changes on cash | 7 | 5 | -1 |
| Increase (decrease) in cash and cash equivalents | -28 | 19 | 16 |
| Cash and cash equivalents at beginning of period | 258 | 223 | - |
| Cash and cash equivalents at end of period | 230 | 258 | - |
CABOT CORP (CBT)
CABOT CORP (CBT)